Synergistic antitumor activity of vitamins C and K-3 on human urologic tumor cell lines

Synergistic antitumor activity of vitamins C and K-3 on human urologic tumor cell lines

Venugopal M; Jamison J M; Gilloteaux J; Koch J A; Summers M; Giammar D; Sowick C; Summers J L

Life Sciences

1996

1996-09

A micro-tetrazolium assay was employed to evaluate vitamin C (VC), vitamin K-3 (VK3) and vitamin C/vitamin K-3 combinations (VC/VK3) for their antitumor activity against eight human urologic tumor cell lines. While the individual vitamins exhibited antitumor activity at high concentrations, co-administration of the vitamin in a VC : VK3 ratio of 100 : 1 potentiated antitumor activity 4- to 61-fold even when exposure times were as short as 1 hour. Administration of exogenous catalase destroyed the antitumor activity of the vitamins and suggested that catalase destroyed the antitumor activity of the vitamins and suggested that hydrogen peroxide and perhaps other reactive oxygen species were involved in the antitumor mechanism of these vitamins. Electron micrographs taken in a previous study demonstrated that vitamin treatment damaged mitochondria and may have impaired ATP synthesis. Analysis of cellular ATP and thiol levels as well as DNA and protein synthesis during the first five hours following a one hour VC/VK3 treatment, revealed: a transient increase in ATP production, a substantial decrease in DNA synthesis, an increase in protein synthesis and a decrease in thiol levels. These results suggested that redox cycling of the vitamin combination increased oxidative stress until it surpassed the reducing ability of the cellular thiols and cellular or genetic damage ensured.

2-methyl-1; 4-naphthoquinone; bladder; cancer-chemotherapy; carcinoma cells; growth; isolated hepatocytes; l-ascorbic-acid; menadione; metabolism; mitomycin-c; oxidative stress; Pharmacology & Pharmacy; prostate; Research & Experimental Medicine; urologic neoplasms; vitamin C

Journal Article

Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).

1389-1400

17

59